Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes

Recruiting N/A Interventional Study
Taybi Linder Syndrome Microcephalic Osteodysplastic Primordial Dwarfism Types I and III Roifman Syndrome Lowry Wood Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
45 (estimated)
Sponsor
Hospices Civils de Lyon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In the human genome, about 750 genes contain one intron excised by the minor spliceosome. These genes are named U12 genes, and these introns, minor or U12 introns. The minor spliceosome comprises its own set of snRNAs, among which U4atac. Its non-coding gene, RNU4ATAC, has been found mutated in Taybi-Linder (TALS), Roifman (RFMN) and Lowry-Wood syndromes (LWS). These rare developmental disorders a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: TALS, RFMN, LWS or other pathology patients * Woman or man * All ages * Presence of bi-allelic mutations of RNU4ATAC or RTTN * Written consent of parents or legal guardian(s) * Affiliation to a Social Security scheme Healthy participants (Parent of the patient) * Woman or man…
Contacts

Sylvie MAZOYER, Dr

04 81 10 65 33

sylvie.mazoyer@inserm.fr

CONTACT

Patrick EDERY, Pr

04 72 12 96 98

charles-patrick.edery@chu-lyon.fr

CONTACT